Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma

泊马度胺 来那度胺 医学 多发性骨髓瘤 内科学 肿瘤科 队列 耐火材料(行星科学) 进行性疾病 沙利度胺 外科 疾病 天体生物学 物理
作者
Tomer M. Mark,Angelica Falkenstein,Jonathan Kish
出处
期刊:Future Oncology [Future Medicine]
卷期号:18 (5): 553-564 被引量:5
标识
DOI:10.2217/fon-2021-1176
摘要

Aim: To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. Materials & methods: US-based community oncologists identified patients with RRMM treated with or without pomalidomide following first-line lenalidomide. Disease response (≥ very good partial response) and progression-free survival were compared. Results: Disease response was 78.6 and 51.7% for pomalidomide (n = 126) and nonpomalidomide cohorts (n = 174), respectively (p < 0.0001). Multivariate adjusted odds of response were 4.5-times greater for pomalidomide cohort (p < 0.0001). Median progression-free survival was not reached for pomalidomide cohort and 16.7 months for nonpomalidomide cohort (log-rank p < 0.01). Conclusion: Following lenalidomide induction in RRMM, pomalidomide is an effective treatment.Plain language summary Treatment options have expanded in recent years for patients with relapsed/refractory multiple myeloma (RRMM) who received lenalidomide as their initial treatment and then either had a period of improvement before the disease worsened or did not respond to the medication at all. Pomalidomide is another MM treatment from the same drug class as lenalidomide. We analyzed the effect of a combination treatment containing pomalidomide versus a combination treatment without pomalidomide in patients with MM who had received routine initial treatment with lenalidomide. US-based community oncologists completed study forms to record patient characteristics and treatment response information. Results showed that patients who received pomalidomide in a combination treatment after initial lenalidomide treatment achieved higher rates of very good partial response or better and longer progression-free survival than those who did not. The results of this analysis suggest that switching to a different class of drugs following the initial treatment may not be warranted after first relapse and pomalidomide-containing combination treatments are a more effective treatment following lenalidomide for patients with RRMM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852应助快乐源泉采纳,获得10
1秒前
linmo发布了新的文献求助10
1秒前
feiling完成签到,获得积分10
1秒前
1秒前
白派派主发布了新的文献求助10
1秒前
dll完成签到 ,获得积分10
1秒前
香蕉觅云应助77sucy采纳,获得10
2秒前
3秒前
3秒前
3秒前
隐形曼青应助猪猪hero采纳,获得10
4秒前
feiling发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
1410完成签到 ,获得积分10
5秒前
Chen发布了新的文献求助10
5秒前
5秒前
万能图书馆应助lieditongxu采纳,获得10
5秒前
bubu发布了新的文献求助10
7秒前
7秒前
8秒前
鹅鹅应助小坤同学采纳,获得10
8秒前
9秒前
南巷发布了新的文献求助10
9秒前
花开富贵发布了新的文献求助20
9秒前
丘比特应助完美的流沙采纳,获得20
9秒前
彭于晏应助77采纳,获得10
10秒前
共享精神应助liuzengzhang666采纳,获得10
10秒前
缥缈易槐完成签到,获得积分10
11秒前
咖啡龙发布了新的文献求助30
11秒前
11秒前
11秒前
XHQ关注了科研通微信公众号
12秒前
CodeCraft应助李明涛采纳,获得10
13秒前
zzz发布了新的文献求助10
13秒前
邹醉蓝完成签到,获得积分10
13秒前
13秒前
14秒前
gao完成签到,获得积分10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988827
求助须知:如何正确求助?哪些是违规求助? 3531183
关于积分的说明 11252671
捐赠科研通 3269809
什么是DOI,文献DOI怎么找? 1804780
邀请新用户注册赠送积分活动 881885
科研通“疑难数据库(出版商)”最低求助积分说明 809021